The objective of the present study was to develop a method for surface electromyographic (EMG) registration of muscle activity in infants, with the perspective of assessing neuromuscular function/prognosis in infants with obstetric brachial plexus palsy (OBPP).
THE E292V VARIANT IN ABCA3 IS OVER-REPRESENTED IN NEWBORNS WITH RESPIRATORY DISTRESS SYNDROME (RDS)
Objective: To determine the prevalence of the E292V variant in infants with and without RDS. Design/Methods: We obtained genomic DNA and clinical data from an unselected cohort of newborns with RDS (RDS, nϭ125, gestational age [GA] 31Ϯ5 wks), newborns with RDS referred for evaluation of familial or atypical RDS (REF, nϭ56 , GA 34Ϯ5 wks), and normal newborns (noRDS, nϭ167, GA 39Ϯ2 wks). We amplified a 637 base pair product that included codon 292 and subjected amplicons to BsrG1 restriction analysis and agarose gel electrophoresis.
Results: Excluding 1 each of concordant twins in the REF and noRDS groups, 3 RDS (2.4%), 5 REF (9.1%), and 2 noRDS (1.2%) infants were heterozygous for E292V (Pϭ0.009). Males and females were equally represented. One infant with E292V in the noRDS group was Black, all others with E292V were White. Symptomatic infants (REFϩRDS) with E292V were more mature than those without E292V (35Ϯ3 vs 32Ϯ5 wks, Pϭ0.007). Duration of mechanical ventilation, and need for supplemental oxygen were not significantly different. Infants with RDS and E292V developed pneumothoraces more frequently (78%) than infants with RDS but without E292V (9%) (PϽ0.001). Six infants had resolution of symptoms within 1 month of birth; the noRDS individuals with E292V remained asymptomatic.
Conclusions: The E292V variant in ABCA3 is significantly more prevalent in infants with RDS than in asymptomatic controls. Patients heterozygous for E292V come to clinical attention by presenting with RDS that is more severe than anticipated for gestational age. E292V may be a genetic influence for the risk and severity of RDS. OBJECTIVE: To determine if variants in SFTPB contribute to the risk of RDS in newborns. METHODS: Using amplified genomic DNA and high throughput, automated sequencing, we genotyped promoter, all translated exons and intervening introns (8.5 kB) of SFTPB in 3 cohorts: 1) anonymous Guthrie cards from the Missouri Newborn Screening Program (Missouri cohort, nϭ1,116; 18% Black, 79% White), 2) newborns with RDS (RDS cohort, nϭ204; 40% Black, 59% White), and 3) newborns without lung disease (Control cohort, nϭ86, 51% Black, 45% White). We used PHASE V2.1, a Bayesian-based haplotype inference program, to computationally reconstruct race and gestational age-specific haplotypes in the RDS and Control cohorts using variant alleles that were present in Ͼ5% of the population.
VARIATION IN THE SURFACTANT PROTEIN B GENE (SFTPB) CONTRIB-UTES TO NEWBORN RESPIRATORY DISTRESS (RDS)
RESULTS: We identified 119 polymorphic sites in SFTPB, including 17 exonic SNPs (10 nonsynonymous) and 5 intronic insertions or deletions. Of the other 97 intronic SNPs, 4 may impact RNA splicing by altering intron-exon junctions. The 121ins2 insertion, the common mutation associated with SP-B deficiency, was identified in 4 heterozygous individuals in the Missouri cohort. Based on Ewens predicted allele frequency, we have identified Ͼ99% of the SNPs with predicted frequencies of Ͼ0.001 in the Missouri cohort, and 92% in the NICU cohort. Despite the difference in cohort size, we found 17 rare (Ͻ4 heterozygous individuals) SNPs in the NICU cohort not detected in the Missouri cohort. There were significant differences in haplotype frequencies between the RDS and Control groups for all race and gestational age cohorts (Pϭ0.01 to 0.05).
CONCLUSIONS: Rare variants contribute approximately 50% of genetic variation in the SFTPB. Rare, private variants and haplotypes are overrepresented in patients with RDS. Genetic variation in the SFTPB contributes to risk of RDS in infants. 
EARLY PATTERNS OF CYTOKINE RESPONSE IN PRETERM INFANTS AND NEURO-COGNITIVE OUTCOME AT 2 YEARS OF AGE

DEPARTMENT OF PSYCHOLOGY, LUND UNIVER-SITY, (SWEDEN)
Background: In a cohort study of preterm infants increased plasma concentrations of proinflammatory cytokines were associated with premature rupture of membranes, arterial hypotension and cerebral damage.
Objective: To evaluate in a follow-up if early postnatal levels of cytokines in preterm infants predict neuro-cognitive outcome at 2 years of age.
Methods: A prospective cohort study of 71 surviving infants Ͻ32 gestational weeks. Plasma concentrations of proinflammatory (TNF-alfa, IL-1beta, IFN-gamma, IL-2, IL-6, IL-8, IL-12) and modulatory (IL-4, IL-10) cytokines were analyzed in umbilical cord and at 6, 24 and 72 h age. Intraventricular hemorrhage (IVH) and white matter brain damage (WMD) was assessed with ultrasound. Neuro-cognitive outcome at 24 months corrected age was evaluated using Bayley Scales of Infant Development (Mental Developmental Index (MDI) and Psychomotor Developmental Index (PDI)) and a standardized neurological examination (Neurological Optimality Score (NOS)).
Results: 64 infants (mean gestational age (GA) 27.1 wks) were assessed at 24 (0.5) months (mean, SD). NOS correlated with both MDI and PDI (rϭ0.60 pϽ0.001 and rϭ0.70 pϽ0.001 respectively). GA correlated with MDI, PDI and NOS ( rϭ0.34 pϭ0.006, rϭ0.42 pϭ0.001 and rϭ0.40, pϭ0.001 respectively). Male gender had lower NOS ( pϭ0.03). Cord levels of the proinflammatory cytokineTNF-alfa were inversely correlated with PDI (rϭ-0.33 pϭ0.014) and levels of the modulatory cytokine IL-10 at 24 h correlated positively with PDI and NOS (rϭ0.42 pϭ0.001 and rϭ0.32, pϭ0.015 respectively) after adjustment for GA and gender. Infants with IVH grade III/IV or WMD (nϭ8) had lower median (range) MDI and NOS, , respectively, as compared to infants without brain injury (nϭ56): 88 (50 -116) and 71 (58 -78), respectively. Differences remained after adjustment for GA, gender and parental education.
Conclusion: An early inflammatory response in preterm infants is associated with perinatal brain injury and might be prognostic for adverse neuro-cognitive outcome at 2 years of age.
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